84 related articles for article (PubMed ID: 9085736)
1. Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia.
Seong D; Giralt S; Fischer H; Hayes K; Glassman A; Arlinghaus R; Xu J; Kantarjian H; Siciliano M; Champlin R
Bone Marrow Transplant; 1997 Mar; 19(6):565-70. PubMed ID: 9085736
[TBL] [Abstract][Full Text] [Related]
2. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow.
Seong D; Thall P; Kantarjian HM; Talpaz M; Swantkowski J; Xu J; Shen Y; Glassman A; Ramagli L; Siciliano MJ
Clin Cancer Res; 1998 Apr; 4(4):861-7. PubMed ID: 9563879
[TBL] [Abstract][Full Text] [Related]
3. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia.
Seong CM; Giralt S; Kantarjian H; Xu J; Swantkowski J; Hayes K; Glassman AB; Khouri I; Korbling M; Thall P; Siciliano MJ; Champlin RE
J Clin Oncol; 2000 May; 18(9):1831-6. PubMed ID: 10784623
[TBL] [Abstract][Full Text] [Related]
4. [Study of the time course of mixed chimerism by fluorescent in situ hybridization in patients with chronic myeloid leukemia after allogenic transplantation of bone marrow].
Vinogradova OA; Savchenko VG; Neverova AL; Diachenko LV; Domracheva EV; Liubimova LS; Mendeleeva LP
Ter Arkh; 2001; 73(7):26-34. PubMed ID: 11523405
[TBL] [Abstract][Full Text] [Related]
5. Durable molecular remission in a patient with chronic myelogenous leukemia and host-derived hematopoiesis after allogeneic bone marrow transplantation.
Wakui M; Okamoto S; Ishida A; Tanosaki R; Mori T; Kawai Y; Ohshima S; Ikeda Y
Bone Marrow Transplant; 1996 Oct; 18(4):801-4. PubMed ID: 8899199
[TBL] [Abstract][Full Text] [Related]
6. Fluorescent in situ hybridization on flow-sorted cells as a tool for evaluating minimal residual disease or chimerism after allogenic bone marrow transplantation.
Cotteret S; Belloc F; Boiron JM; Bilhou-Nabera C; Dumain P; Boyer C; Lacombe F; Reiffers J; Bernard P
Cytometry; 1998 Oct; 34(5):216-22. PubMed ID: 9822307
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic role of conventional cytogenetics and fluorescence in situ hybridization (FISH) in chronic myeloid leukemia patients.
Jha CB; Kucheria K; Choudhary VP
Kathmandu Univ Med J (KUMJ); 2006; 4(2):171-5. PubMed ID: 18603893
[TBL] [Abstract][Full Text] [Related]
8. [Molecular cytogenetic monitoring of chimerism and minimal residual disease in patient with chronic myeloid leukemia after allogenic and syngenic bone marrow transplantation].
Vinogradova OA; Savchenko VG; Domracheva EV; Liubimova LS; Ol'shanskaia IuV; Diachenko LV; Parovichnikova EN; Mendeleeva LP; Zakharova AV
Ter Arkh; 2002; 74(7):38-44. PubMed ID: 12181833
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of genetic markers in chronic myelogenous leukemia patients after bone marrow transplantation.
Zámecníková A; Kri an P; Mistrík M
Neoplasma; 2000; 47(5):299-302. PubMed ID: 11130247
[TBL] [Abstract][Full Text] [Related]
10. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
[TBL] [Abstract][Full Text] [Related]
11. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion.
Jootar S; Pornprasertsud N; Petvises S; Rerkamnuaychoke B; Disthabanchong S; Pakakasama S; Ungkanont A; Hongeng S
Leuk Res; 2006 Dec; 30(12):1493-8. PubMed ID: 16839603
[TBL] [Abstract][Full Text] [Related]
13. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment.
Seong DC; Kantarjian HM; Ro JY; Talpaz M; Xu J; Robinson JR; Deisseroth AB; Champlin RE; Siciliano MJ
Blood; 1995 Sep; 86(6):2343-9. PubMed ID: 7662980
[TBL] [Abstract][Full Text] [Related]
14. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
15. A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
Saito Y; Uzuka Y; Sakai N; Suzuki S; Toyota T
Bone Marrow Transplant; 2000 Jun; 25(11):1209-11. PubMed ID: 10849535
[TBL] [Abstract][Full Text] [Related]
16. [The application of fluorescence in situ hybridization in detecting chronic myeloid leukemia].
Qiu HR; Miao KR; Wang R; Qiao C; Zhang JF; Zhang SJ; Qian SX; Xu W; Li JY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):207-10. PubMed ID: 19350518
[TBL] [Abstract][Full Text] [Related]
17. Non-random involvement of chromosome 13 in patients with persistent or relapsed disease after bone-marrow transplantation for chronic myeloid leukemia.
Chase A; Pickard J; Szydlo R; Coulthard S; Goldman JM; Cross NC
Genes Chromosomes Cancer; 2000 Mar; 27(3):278-84. PubMed ID: 10679917
[TBL] [Abstract][Full Text] [Related]
18. Detection of residual host cells after bone marrow transplantation using non-isotopic in situ hybridization and karyotype analysis.
Wessman M; Popp S; Ruutu T; Volin L; Cremer T; Knuutila S
Bone Marrow Transplant; 1993 Apr; 11(4):279-84. PubMed ID: 8485475
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease in chronic myeloid leukaemia.
Cross NC
Hematol Cell Ther; 1998 Oct; 40(5):224-8. PubMed ID: 9844816
[TBL] [Abstract][Full Text] [Related]
20. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
van Rhee F; Szydlo RM; Hermans J; Devergie A; Frassoni F; Arcese W; de Witte T; Kolb HJ; Niederwiser D; Jacobsen N; Gahrton G; Bandini G; Carreras E; Bacigalupo A; Michallet M; Ruutu T; Reiffers J; Goldman JM; Apperley J; Gratwohl A
Bone Marrow Transplant; 1997 Oct; 20(7):553-60. PubMed ID: 9337056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
